Epstein Secrets

ply-To: Cardiology Alert <I Email not displaying correctyNiaw it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study. presented at the 2017 American College of Cardiology Scientific Session in Was

hould discuss their LDL cholesterol with their physician and consider whether they need to lower it further." Reference Sabatine MS. Giugliano RP, Keech AC, et al. N Engl J Med. 2017;doi:NEJMoa1615664 http://www.nejm.orq/doUpdf/10.1056/NEJMoa 1615664 Sabatine M. Primary Results of the Further Cardiovas

y Alert < EFTA00447987 Entail not displaying coirectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2017 American College of Cardiology Scientific Session in Was

hould discuss their LDL cholesterol with their physician and consider whether they need to lower it further." Reference Sabatine MS, Giugliano RP, Keech AC, et al. N Eng! J Med. 2017;doi:NEJMoa1615664 http://www.nejm.orgidoi/pdf/10.1056/NEJMoa1615664 Sabatine M. Primary Results of the Further Cardiovas

Reply-To: Cardiology Alert E— ail not displaying conectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2017 American College of Cardiology Scientific Session in Was

hould discuss their LDL cholesterol with their physician and consider whether they need to lower it further." Reference Sabatine MS, Giugliano RP, Keech AC, et al. N Eng! J Med. 2017;doi:NEJMoa1615664 http://www.ne m.orgidoi/pdftl0.1056/NEJMoa1615664 Sabatine M. Primary Results of the Further Cardiovas